Proxy Results (Form 8-K)

On July 14, 2026, Decoy Therapeutics Inc. (the "Company") convened its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of May 22, 2026, the record date for the Annual Meeting, there were 531,968 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 225,548, or 42.4%, were present in person or represented by proxy, which constituted a quorum.

At the Annual Meeting, the stockholders voted and: (1) re-elected or elected each of the Company's three nominees for Class II director; (2) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting; and (3) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.

Proposal 1. To elect three Class II directors to serve until the 2029 annual meeting or until their successors are duly elected and qualified:

Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting:

Proposal 3. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: